MicroBiome’s diabetes drug shows promise
Broomfield-based MicroBiome reported that the research drug called NM504 kept blood glucose levels within normal limits for patients involved in a four-week clinical trial. The research drug works by shifting a diabetic or pre-diabetic person’s gut bacteria to make it behave more like a healthy person’s gut bacteria, said Barbara Lindheim, a company spokeswoman.
Studies have shown that Type 2 diabetics typically have microbial imbalances…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!